A federal appeals court has significantly restricted access to mifepristone, a common abortion medication, by blocking its distribution through the mail. The New Orleans-based 5th U.S. Circuit Court of Appeals now mandates that the abortion pill be dispensed solely in person at clinics.
Court Ruling Details
The ruling asserted that the FDA's actions facilitating abortion undermined Louisiana's policy recognizing an unborn child as a legal person from conception. This decision marks a departure from the historical judicial deference typically given to the Food and Drug Administration's judgments on drug safety and regulation.
Legal Implications
The ruling sets the stage for a likely appeal to the Supreme Court, which previously preserved access to mifepristone in 2024 by sidestepping core legal issues. The decision applies nationwide, effectively ending mail-order access to the medication across the United States.
Related: Supreme Court Upholds FDA Regulation on Popular Abortion Drug Mifepristone
